These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26305791)

  • 1. Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
    Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
    PLoS One; 2015; 10(8):e0136826. PubMed ID: 26305791
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
    Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
    PLoS One; 2014; 9(8):e104870. PubMed ID: 25137071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
    Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
    Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
    Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.
    Zhu T; Liu CL; Zhang YF; Liu YH; Xu FP; Zu J; Zhang GC; Li XR; Liao N; Wang K
    Breast Cancer Res Treat; 2016 Feb; 156(1):117-24. PubMed ID: 26936755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
    Hahn A; Schlotter CM; Rossmanith WG; Ulmer HU; Staiger HJ; Villena C
    In Vivo; 2014; 28(2):235-41. PubMed ID: 24632979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
    Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
    Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Chen SC; Chang HK; Lin YC; Cheung YC; Tsai CS; Leung WM; Hsueh S; Chen MF
    Onkologie; 2005 Jun; 28(6-7):339-44. PubMed ID: 15933422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
    Buzdar AU; Valero V; Ibrahim NK; Francis D; Broglio KR; Theriault RL; Pusztai L; Green MC; Singletary SE; Hunt KK; Sahin AA; Esteva F; Symmans WF; Ewer MS; Buchholz TA; Hortobagyi GN
    Clin Cancer Res; 2007 Jan; 13(1):228-33. PubMed ID: 17200359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
    Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J
    Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
    Anan K; Tanaka M; Yoshinaga Y; Maeda S; Yamaguchi Y; Hayashi M; Tanaka M; Kamata Y; Mashino K; Yamamoto Y; Nishimura J; Matsuo S; Toyoshima S; Tamura K; Mitsuyama S;
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):45-50. PubMed ID: 25596678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
    Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
    J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
    Ando M; Yamauchi H; Aogi K; Shimizu S; Iwata H; Masuda N; Yamamoto N; Inoue K; Ohono S; Kuroi K; Hamano T; Sukigara T; Fujiwara Y
    Breast Cancer Res Treat; 2014 Jun; 145(2):401-9. PubMed ID: 24728578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
    Tong F; Zhou B; Yang D; Cao Y; Liu P; Liu H; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1147-52. PubMed ID: 12145994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.